Kaitai Capital Research
Investment Thesis
Kaitai Capital (凯泰资本) is a Hangzhou-based venture capital manager whose stated motto is research-driven investing: "the economy is the expression of technology, and the economy originates from technology." The firm describes innovation investing as a delayed-gratification profession that looks for value beyond the immediate horizon and explores the essence of uncertain trends. It says it has the patience to walk alongside entrepreneurs, empower founders, and create value for investors.
The firm lists its investment philosophy as trend investing, value investing, ecosystem investing, concentrated investing, and contrarian investing. Its fund culture is summarized as simple, real, and transparent. The management model stresses systematic management, programmatic decisions, and team execution.
Sector Focus
The website names three investment areas, and the portfolio page groups companies the same way:
- Artificial intelligence. Tool intelligence and its digital value, general-intelligence disruption, generative AI applied to vertical industries, plus AI, Web3, blockchain, big data, cloud, intelligent computing and large models. Portfolio sub-tags: AI Infra, AI agent applications, embodied intelligence.
- Life sciences. Unmet medical needs, globally leading biotechnology industrialization and disruptive biotech platforms. Portfolio sub-tags: disease areas, technology platforms, biomanufacturing and medical services. Partners cite antibodies, targeted small molecules, gene and cell therapy, multispecific drugs, drug delivery, CRO and AI-enabled drug discovery.
- Technology consumer. Consumer, media and entertainment companies, including games, content, social and food and beverage.
Recent news shows a strong push into AI compute hardware: 3D stacked compute-in-memory edge AI chips, optical interconnect, and AI-native commerce and organizations.
Stage Focus
The site does not publish a stage policy. Partner bios mention early and mid-early stage investing in gene and cell therapy and in AI and Web3, and growth-stage life-science projects. Portfolio news includes a Pre-A round (Heluo Xintu, RMB 150M) and a lead role in Guangyu Xinchen. Stage is therefore inferred as seed through growth, with low confidence.
Check Size
Not disclosed. No check size is stored.
Lead Tendency
The firm's own news uses both "led" (Guangyu Xinchen) and "exclusively invested" (K2 Lab) language, as well as plain "invested" for others. Lead tendency is recorded as both.
Recent Activity
Official news posts dated 2026-10-28 and later report investments in Micro-Nano Core (微纳核芯) (3D compute-in-memory chip), K2 Lab (A2A-native commerce, exclusive investment) and a lead in Guangyu Xinchen (edge AI inference chips). In September 2026 it announced an investment in Guoke Guangxin (国科光芯) (optical interconnect). In August 2026 portfolio company Heluo Xintu closed a RMB 150M Pre-A round on an iPSC platform for artificial blood. The firm publishes monthly portfolio updates, so it appears to be actively deploying.
Portfolio Highlights
The portfolio page lists roughly 120 distinct companies across AI, life sciences and consumer technology. Names include Wumo Technology (dexterous robotic hands), Deep Intelligence (multi-agent drug R&D), PaXini Perception, Kangaroo Cloud (袋鼠云), WhaleOps (白鲸开源), Jinke Culture (Talking Tom), Perfect World, CARsgen, Abcuro, OncoC4 and Rgenta. Stage and date of each investment are not shown on the page.
Team
Founder and CEO Xu Yonghong (徐永红) entered venture capital in 1999 and founded Kaitai Capital in 2009. He previously built Wanxiang Venture, the Zhejiang Innovation Industry Fund and the Shenzhen Houde Qianhai fund. The team lists:
- Xi Mingxian, Managing Partner, chief AI expert, ex-Huawei and Alibaba
- Fang Liangchang, Managing Partner, real estate and the Nanjing fund
- Wang Linfu, Managing Partner and chief risk officer
- Huang Shizhuan, Managing Partner, life sciences, investment committee member
- Xu Jinzhong, Managing Partner, chief investment officer for digital industry
- Jin Qi, Managing Partner, life sciences
- Li Xianxian, Managing Partner, multispecific drugs
- Duan Junkai, Managing Partner, AI large models and applications
- Yuan Jiangmiao, Huang Zehua, Managing Partners
- Wang Yanan, President and rotating CEO
- Yu Guangwei, Yu Yingfei, Presidents (AI and Web3 early stage, based in Beijing and Hangzhou)
Decision Process
Decisions go through an investment decision committee with several managing partners as members. The firm describes programmatic decision making and team execution, so it is recorded as an investment committee process.
Founder Preferences
The motto "invest in people, invest in the future, no forcing" suggests a preference for long-term relationships with technically deep founders. The firm cites deep technical backgrounds (Huawei, Alibaba, pharma) among its own partners.
Geographic Focus
China-focused, headquartered in Hangzhou (Yuhuangshan South Fund Town) with a Nanjing fund and Beijing presence. Portfolio also includes US and global biotech names such as OncoC4, Abcuro, Rgenta, Totient and Redesign. Business plans go to [email protected].